FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC By Ogkologos - August 5, 2026 105 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... December 6, 2019 Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... March 24, 2021 Science Surgery: ‘Can cancers develop in the heart?’ March 30, 2021 ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ February 10, 2019 Load more HOT NEWS ‘Jeopardy!’ Legend James Holzhauer Donates Portion Of Winnings To Cancer Walk... Cancer in My Community: The Roadblocks to Receiving Cancer Care in... Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected... Breathing Amidst Uncertainty
